美年健康(002044) - 2024 Q2 - 季度业绩预告

I. Estimated Current Period Performance Meinian Healthcare projects a net loss for the first half of 2024, with revenue decreasing and key profit metrics turning from positive to negative - The company anticipates a negative net profit for the first half of 2024[2] Key Financial Indicators for H1 2024 Performance Forecast | Project | Current Period (Estimated) | Prior Year Period | Change | | :--- | :--- | :--- | :--- | | Operating Revenue | CNY 4.06 billion – CNY 4.35 billion | CNY 4.451 billion | Year-on-year decrease | | Net Profit Attributable to Shareholders of Listed Company | Loss: CNY 177 million – CNY 257 million | Profit: CNY 5.23 million | Turned from profit to loss | | Net Profit Excluding Non-recurring Gains and Losses | Loss: CNY 187 million – CNY 267 million | Profit: CNY 4.28 million | Turned from profit to loss | | Basic Earnings Per Share | Loss: CNY 0.05/share – CNY 0.07/share | Profit: CNY 0.0013/share | Turned from profit to loss | II. Communication with Accounting Firms The financial data disclosed in this performance forecast are preliminary estimates by the company's finance department and have not yet been audited by a certified public accountant - The financial data related to this performance forecast have not been audited by a certified public accountant[4] III. Explanation of Performance Changes The company's H1 performance decline is due to industry seasonality, a high prior-year base, delayed customer visits, reduced single-store revenue, increased fixed costs, and higher share-based payment expenses; H2 strategies focus on diversified revenue, cost efficiency, and increased per-capita consumption for sustainable growth - The company adheres to a core strategy of 'quality assurance, revenue growth, efficiency improvement, and cost reduction,' driven by medical service quality, expanding high-quality clients, optimizing client structure, and focusing on digital operations and empowerment[4] - The health check-up industry, in which the company operates, exhibits strong seasonality, with the first half of the year typically being an off-peak season[5] Reasons for H1 Performance Changes - H1 revenue decreased year-on-year primarily due to a higher base in Q1 of the prior year influenced by external factors, and a significant increase in holiday travel affecting delayed visits by signed customers[5] - The main reasons for the H1 profit decline include decreased average single-store revenue, insufficient revenue generation from increased controlled stores during the off-peak season, and fixed expenses such as rent and personnel salaries during this period[5] - Expenses related to share-based payments for the employee stock ownership plan increased by approximately CNY 30 million compared to the same period last year[5] H2 Operating Strategies and Outlook - The company expects business to gradually pick up in Q3 of the second half, actively implementing measures to scientifically arrange reception schedules for the peak season[5] - H2 will leverage three key strategies—diversified revenue, cost reduction and efficiency improvement, and increased per-capita consumption—to achieve 'digitally driven, diversified growth and high-quality profit-oriented sustainable growth'[5] - Specific strategies include optimizing client structure, strengthening 'group-to-individual check-up conversion' and private domain traffic operations, deepening key discipline development (e.g., capsule endoscopy robots, genetic products, brain health), enhancing digital AI technology empowerment in medical services, promoting cost reduction and efficiency, and strengthening brand credibility and collaborations with research institutions[5] IV. Other Related Information The company reminds investors that this performance forecast is a preliminary estimate, with final financial data subject to the officially disclosed H1 2024 report, advising caution in investment decisions and awareness of risks - This performance forecast represents preliminary estimates by the company's finance department, with final financial data to be based on the officially disclosed 2024 semi-annual report[6] - Investors are advised to exercise caution in decision-making and be aware of investment risks[6]